|
EXHIBIT 10.57
AMENDMENT NO. 4 TO
PATENT AND TECHNOLOGY LICENSE AGREEMENT
DATED JULY 31, 1994
This is AMENDMENT NO 4 effective
this 1st day of August
, 2006, to the Patent and Technology License Agreement dated
July 20, 1994 (as amended, the AGREEMENT) is between THE BOARD
OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (BOARD), an agency of
the State of Texas, on behalf of THE UNIVERSITY OF TEXAS M. D.
ANDERSON CANCER CENTER (MDA), located at 1515 Holcombe Boulevard,
Houston, Texas 77030, and INTROGEN THERAPEUTICS, INC, a Texas
corporation, located at 301 Congress Avenue, Suite 1850,
Austin, Texas 78701 (LICENSEE).
RECITALS
|
A.
|
|
BOARD is the owner of several new inventions
(collectively, these new inventions are referred to as Technologies
Numbered 28-36).
|
|
|
|
|
|
B.
|
|
LICENSEE is interested in developing and
commercializing new technologies directed to the treatment of
cancel, and other threatening diseases, to which end LICENSEE, MDA
and BOARD entered into the AGREEMENT noted hereinabove.
|
|
|
|
|
|
C.
|
|
LICENSEE wishes to add Technologies Numbered
28-36 under PATENT RIGHTS as defined in Section 2.3 of the
AGREEMENT.
|
|
|
|
|
|
D.
|
|
And, BOARD wishes to grant LICENSEE rights to
Technologies Numbered 28-36 to promote its practical development
for the benefit of the MDA’s patients and for the benefit of
the people of the state of Texas.
|
NOW, THEREFORE, in consideration for the
mut
|
